Field Service Engineer

New spectrometry technique could aid formulation development. September 2, 2026 A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That's the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique. According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood. "This is where [this approach] can help with the bioprocessing and formulation," he says, as structural changes "can affect the lifespan [of the product] and lead to issues, such as aggregation." Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information. The challenge is understanding the link between these things within a heterogeneous sample, he says. To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says. He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states. Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique. Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

Bruker Drives Major Advances in Detector Technology for Semiconductor and Nanostructure Analysis - Electronics / Instrumentation / RFID - Bruker Corporation. / | Bruker Drives Major Advances in Detector Technology for Semiconductor and Nanostructure Analysis | | / | NewswireTODAY - /newswire/ - Liverpool, United Kingdom, 2026/08/31 - Large multi-segment EDS detector sets new benchmark for speed and resolution - Bruker.com. NASDAQ: BRKR | | / | Your Banner Ad Here instead - Showing along with ALL Articles covering Electronics / Instrumentation / RFID Announcements Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How! | | / | Discover more Try CAD Software News Take Journalism Courses Bruker today announced the launch of the XFlash(R) 7200 FIRE, the world's first inclined large-area Energy-Dispersive Spectroscopy (EDS) detector for Scanning Electron Microscopy (SEM) built on Bruker's revolutionary four-segment Silicon Drift Detector (SDD) architecture. Representing the most significant advancement in EDS detector design in decades, the XFlash(R) 7200 FIRE establishes a new benchmark for elemental analysis in SEM by overcoming the fundamental throughput and energy-resolution limitations of conventional large-area detectors. The latest addition to the Bruker QUANTAX(R) product family features a novel concept that combines the efficiency of a large-area detector with the count-rate performance of four independently operating SDD segments. This innovative architecture unlocks levels of analytical performance that were previously unattainable with conventional single-segment detector designs. With the large active area of 200 mm^2, the XFlash(R) 7200 FIRE delivers extraordinary collection solid angles and at the same time it ensures the higher throughput required for drastically reduced acquisition times without compromising data quality. The detector's windowless design maximizes detection efficiency, particularly in the low-energy range, thereby enabling highly accurate quantitative elemental analysis with outstanding light element sensitivity. By combining exceptional energy resolution with unprecedented count-rate capability, the XFlash(R) 7200 FIRE opens new possibilities for demanding analytical applications, such as battery materials containing light elements, beam-sensitive biological specimens, and semiconductor devices with demanding peak overlap, spatial-resolution, and throughput requirements. "The XFlash(R) 7200 FIRE is the dream of every advanced EDS user," said Dr. Purvesh Soni, Bruker Senior Application Scientist. "It is truly the next generation of EDS detectors, enabling maximum X-ray collection efficiency at best spectral resolution." "Thanks to the segmented detector design, the XFlash(R) 7200 FIRE delivers specifications beyond anything previously available on the market. It paves the way for scientists and engineers to solve some of today's most pressing materials challenges and to drive innovation in areas ranging from batteries and semiconductors to improving quality control in advanced manufacturing," added Dr. Sebastian Schmidt, Bruker Product Manager EDS. "Additionally, it is ideally suited for use in combination with complementary Bruker QUANTAX products, such as the eWARP and XTrace 2." These innovations further advance Bruker's leadership in SEM EDS detector technology, empowering researchers with the performance and capabilities needed to unlock deeper insights into increasingly complex materials and devices. About Bruker Corporation Leader of the Post-Genomic Era Bruker (bruker.com) is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with its customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy, as well as in industrial and cleantech research, and semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, proteomics and multiomics, spatial and single-cell biology, structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. | | / | Your Banner Ad Here instead - Showing along with ALL Articles covering Electronics / Instrumentation / RFID Announcements Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How! | | / | Agency / Source: Bruker Corporation | | / | Availability: All Regions (Including Int'l) | | / | Traffic Booster: [/] Quick NewswireToday Visibility Checker | | / | Distribution / Indexing: [+] / [Company listed above is a registered member of its network. Content made possible by PRZOOM / PRTODAY indexing services] | | / | # # # | | / | Your Banner Ad showing on ALL Electronics / Instrumentation / RFID articles, CATCH Visitors via Your Competitors Announcements! Company website links NOT available to basic submissions | / | It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source. | | / | For more information, please visit: Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now! XFlash(R) 7200 FIRE | Bruker | Contact: Dr. Heiko Ress - Bruker.com +49 721 50997-0 heiko.ress[.]bruker.com | PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT NewswireToday — Limelon Advertising, Co.. Issuers of articles are solely responsible for the accuracy of their content. Its complete disclaimer appears here. IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Bruker Corporation securities in any jurisdiction including any other companies listed or named in this release. | Read Electronics / Instrumentation / RFID Most Recent Related Newswires: | (C) 2005-2026 NewswireToday - Limelon Advertising, Co. Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS | | newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as NewswireToday — Limelon Advertising, Co. declined their partnership offer in 2013 | | PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com) NewswireToday — Limelon Advertising, Co. use cookies to enhance your experience. By continuing to visit this site you agree to its use of cookies. More info

Bruker takes majority stake in dutch MIMETAS as organoid technologies move into the mainstream. The U.S. analytical technology group is acquiring a majority stake in Dutch organ-on-a-chip specialist MIMETAS, bringing human tissue models into its broader portfolio of multiomics, spatial biology and preclinical imaging. The deal is another sign that organoids and microphysiological systems are moving from specialized research tools toward integrated platforms for drug discovery. Bruker is expanding its life sciences business into human physiology-relevant disease models with a majority investment in MIMETAS, a Leiden-based developer of organ-on-a-chip platforms and advanced human tissue models. Financial terms were not disclosed. MIMETAS will continue to operate under its existing brand and management. The strategic logic is straightforward: MIMETAS provides the human tissue models, while Bruker brings technologies for proteomics, metabolomics, NMR, spatial biology and preclinical imaging. The companies aim to connect the two into integrated workflows for disease research, compound testing and drug development. MIMETAS' flagship OrganoPlate platform uses microfluidic tissue cultures in a format compatible with standard high-throughput laboratory workflows. Its portfolio includes models for vascularized tissues, liver, lung and gut, as well as organoid-derived models. The company also offers OrganoReady tissue and organoid products, instrumentation and contract research services. "Human physiology-relevant tissue and disease models are becoming increasingly important for understanding disease biology and evaluating therapeutic candidates," Bruker CEO Frank H. Laukien said. He described microphysiological systems (MPS), also known as New Approach Methodologies (NAMs), as having a "bright future" in drug discovery, development and preclinical testing. From organoids to industrial workflows. The MIMETAS transaction matters because it is less about a single organoid model than about the industrialization of human-relevant biology. Organoids, 3D microtissues and organ-on-a-chip systems can reproduce aspects of human tissue architecture and function that are difficult to capture with conventional two-dimensional cell cultures. In drug development, their potential applications range from target validation and disease modeling to efficacy and toxicity testing. They are not, however, a universal replacement for animal studies. Standardization, reproducibility, scalability and the ability of individual models to predict clinical outcomes remain important challenges. The growing interest in combining these models with automated screening, imaging and molecular profiling reflects an attempt to address some of those limitations. That is where Bruker's position becomes particularly relevant. Instead of simply adding another cell model to its portfolio, the company can connect human tissue systems with increasingly sophisticated molecular and spatial readouts. The resulting data could ultimately feed into computational and AI-based drug discovery workflows. Europe is already consolidating the field. Bruker's move also fits into a broader European consolidation of technologies around organoids, 3D cell models and advanced in-vitro testing. Merck KGaA acquired Dutch organoid specialist HUB Organoids in late 2024. The Utrecht-based company developed organoid technologies that complement Merck's existing life sciences portfolio of cell culture products, reagents and research tools. Sartorius made a similar move in 2025, agreeing to acquire MatTek, including Visikol, from Swedish BICO Group for $80 million. The transaction added 3D microtissue models and primary cells to Sartorius' cell technology portfolio. MatTek's models are designed to mimic human tissue structure and function and complement Sartorius' cell analysis instruments, reagents and AI-supported models. Sartorius completed the acquisition on July 1, 2025. The transaction also illustrates a wider reshaping of the sector. BICO itself had acquired MatTek in 2021 but later decided to divest the business as it refocused on lab automation and selected workflows. In other words, the technology is moving in two directions at once: specialist companies are developing increasingly sophisticated human models, while larger life sciences companies are integrating those models into broader laboratory and drug-development ecosystems. A European strength with global ambitions. There is a notable European footprint in this emerging market. MIMETAS and HUB Organoids are both Dutch companies, while Sartorius has built its cell technology strategy around its German base. Switzerland's InSphero, meanwhile, has established itself as another major European player in 3D cell and microtissue models. Roche is building its own research institute to develop organoids. There are loads of companies around in UK, Germany (TissUse, Cellbricks in Berlin), Austria (a:head, HeartBeat.Bio in Vienna), in Scandinavia and elsewhere working on special plattform technologies or using organoids for drug development themselves like Indivumed in Hamburg. This gives Europe a meaningful position in a field that sits at the intersection of biotechnology, laboratory technology and drug development. The regulatory environment is also moving in the same direction, although adoption remains uneven. The broader NAM concept encompasses technologies ranging from organoids and organ-on-a-chip systems to computational models and other human-relevant approaches intended to improve or reduce the use of traditional animal testing. The real prize is the data. For Bruker, the long-term opportunity may therefore lie less in selling organoids than in capturing better biological data from them. A human tissue model becomes considerably more valuable when it can be combined with automated experiments, high-content imaging, spatial biology, proteomics and metabolomics. That creates a potential feedback loop in which increasingly human-relevant models generate increasingly detailed datasets for drug discovery and, eventually, AI models. This is also why the MIMETAS deal belongs in the wider conversation about the changing infrastructure of drug R&D. The industry is gradually moving away from isolated tools toward connected platforms that link biology, measurement, automation and computation. Bruker's investment in MIMETAS is another indication that organoids and microphysiological systems are no longer being viewed simply as promising alternatives to conventional cell culture. They are increasingly becoming part of the commercial infrastructure for the next generation of drug discovery.